476 related articles for article (PubMed ID: 17464248)
1. Histone deacetylase inhibitor and demethylating agent chromatin compaction and the radiation response by cancer cells.
Bar-Sela G; Jacobs KM; Gius D
Cancer J; 2007; 13(1):65-9. PubMed ID: 17464248
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
5. Novel approaches on epigenetics.
Papait R; Monti E; Bonapace IM
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):264-75. PubMed ID: 19333872
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
Schneider-Stock R; Ocker M
IDrugs; 2007 Aug; 10(8):557-61. PubMed ID: 17665331
[TBL] [Abstract][Full Text] [Related]
7. The emerging role of epigenetic modifications and chromatin remodeling in spinal muscular atrophy.
Lunke S; El-Osta A
J Neurochem; 2009 Jun; 109(6):1557-69. PubMed ID: 19383090
[TBL] [Abstract][Full Text] [Related]
8. Targeting the epigenome for the treatment and prevention of lung cancer.
Schrump DS; Nguyen DM
Semin Oncol; 2005 Oct; 32(5):488-502. PubMed ID: 16210090
[TBL] [Abstract][Full Text] [Related]
9. The potential role of epigenetic therapy in multiple myeloma.
Smith EM; Boyd K; Davies FE
Br J Haematol; 2010 Mar; 148(5):702-13. PubMed ID: 19912222
[TBL] [Abstract][Full Text] [Related]
10. Epigenetics and cancer treatment.
Kristensen LS; Nielsen HM; Hansen LL
Eur J Pharmacol; 2009 Dec; 625(1-3):131-42. PubMed ID: 19836388
[TBL] [Abstract][Full Text] [Related]
11. Rational development of histone deacetylase inhibitors as anticancer agents: a review.
Acharya MR; Sparreboom A; Venitz J; Figg WD
Mol Pharmacol; 2005 Oct; 68(4):917-32. PubMed ID: 15955865
[TBL] [Abstract][Full Text] [Related]
12. Small molecule modulators in epigenetics: implications in gene expression and therapeutics.
Swaminathan V; Reddy BA; Ruthrotha Selvi B; Sukanya MS; Kundu TK
Subcell Biochem; 2007; 41():397-428. PubMed ID: 17484138
[TBL] [Abstract][Full Text] [Related]
13. Histone acetylation and chromatin signature in stem cell identity and cancer.
Shukla V; Vaissière T; Herceg Z
Mutat Res; 2008 Jan; 637(1-2):1-15. PubMed ID: 17850830
[TBL] [Abstract][Full Text] [Related]
14. DNA methyltransferase inhibitor RG108 and histone deacetylase inhibitors cooperate to enhance NB4 cell differentiation and E-cadherin re-expression by chromatin remodelling.
Savickiene J; Treigyte G; Jazdauskaite A; Borutinskaite VV; Navakauskiene R
Cell Biol Int; 2012 Nov; 36(11):1067-78. PubMed ID: 22845560
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
Emanuele S; Lauricella M; Tesoriere G
Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
Santini V; Gozzini A; Ferrari G
Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
[TBL] [Abstract][Full Text] [Related]
17. Chromatin-remodelling mechanisms in cancer.
Lafon-Hughes L; Di Tomaso MV; Méndez-Acuña L; Martínez-López W
Mutat Res; 2008; 658(3):191-214. PubMed ID: 18403253
[TBL] [Abstract][Full Text] [Related]
18. Switching on epigenetic therapy.
Karberg S
Cell; 2009 Dec; 139(6):1029-31. PubMed ID: 20005793
[TBL] [Abstract][Full Text] [Related]
19. H3K9 acetylation and radial chromatin positioning.
Strasák L; Bártová E; Harnicarová A; Galiová G; Krejcí J; Kozubek S
J Cell Physiol; 2009 Jul; 220(1):91-101. PubMed ID: 19248079
[TBL] [Abstract][Full Text] [Related]
20. Epigenetics of lung cancer.
Bowman RV; Yang IA; Semmler AB; Fong KM
Respirology; 2006 Jul; 11(4):355-65. PubMed ID: 16771905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
